Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
about
Recent developments in treatment of latent tuberculosis infectionStrategies for treating latent multiple-drug resistant tuberculosis: a decision analysisPotential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infectionCost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants.Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis.Tuberculosis prevention versus hospitalization: taxpayers save with preventionTuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis.Priorities for screening and treatment of latent tuberculosis infection in the United StatesIsoniazid for preventing tuberculosis in non-HIV infected persons.Revisiting rates of reactivation tuberculosis: a population-based approachAdverse reactions to first-line antituberculosis drugs.Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil.The rational use of potentially hepatotoxic medications in patients with underlying liver disease.A systematic review of economic evaluations of chemoprophylaxis for tuberculosis.Tuberculosis in pregnancy: current recommendations for screening and treatment in the USA.Tuberculosis in pregnancy - case studies and a review of Australia's screening process.Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in childrenTargeted tuberculosis contact investigation saves money without sacrificing health.Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness.Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations.Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam.Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.Tuberculosis prevention and control in long-term-care facilities for older adults.Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis.Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis.Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee.Differences in contributing factors to tuberculosis incidence in U.S. -born and foreign-born persons.Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations.Measurement of health preferences among patients with tuberculous infection and disease.Prevalence of tuberculin skin test positivity in clinical population in New York City.
P2860
Q24630473-E0E79595-6C87-4914-90DF-8A70D9A135DFQ28478920-C1A6E87A-024B-47E9-AB71-72F4BCFE8C2BQ28479103-5D15068F-2E8E-4DEE-A79F-83A8151501C6Q33247229-B75366ED-1AF5-484C-8533-517AD37F156DQ33702764-34450140-903D-4F5B-9BCB-3B5E57C6E30CQ33726947-5C877EAA-313E-4FFF-805E-19803CDFFF60Q33892956-27AC942B-69AC-4B90-AC0E-C37FFD16F031Q33895875-5E72E132-D8DB-4DC7-B727-A05BC7163C4EQ33900621-7058DC1B-74D0-4550-B3EB-B1730B9343FEQ34065641-5E9CDA1B-D60F-4A97-A888-ADA72C9252F3Q34497890-A0EF4B49-1C5E-42C1-8060-2E1EC2DD7DDEQ34672436-557AB772-DE2D-48BC-BFCC-0F95ACD032EBQ35194515-497EA555-2FBA-4A4A-BA38-01BF846FA602Q35503563-C2A01D40-9504-45A1-9BCC-8894EF82D545Q35917489-DB4E934E-5DA6-48D5-AF25-A7F31F6628DDQ36585938-FA5B73C7-0066-4522-9C73-86028BDB387BQ37308287-285F1405-5461-4440-846F-CFB37DBA8537Q37391089-2BE72EDF-3A98-4033-A461-5B9F0421AC9FQ39511808-9180C4A1-C1C5-472F-A6C5-65A9B55A43F7Q40735163-06EDD1DF-516C-4AE3-AB21-186AB527149BQ41723294-0360316E-074F-4CBF-A715-96A06C816FEEQ42110466-1597CE19-E062-41EE-A8C7-3D76FF4C8EAFQ44157851-2F546E18-8DA7-4471-945A-CAF90DAAF4D9Q44381410-85195B00-E909-46BC-9930-31CE71BDF1EAQ44531038-03BFAE1B-D704-4321-9F2F-50AAC26E47F7Q44917828-59188637-A806-465A-9C8E-65CA10EB72C0Q45940596-37F119AD-16DC-47C6-92C0-5AB1A276A186Q45988272-78279663-3623-40E8-8242-E7EDF8C04AAEQ46624692-8FD74967-1432-4D44-908B-092F5FCD91F8Q51151355-1450C0B6-F0FC-484B-AFD7-4AACA6459374Q51701677-B81ED8D3-3551-49BB-814F-EADABEEEE8D7Q51876289-12A24A13-4271-4C4A-8F43-5BBBA358BE02
P2860
Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Monitored isoniazid prophylaxi ...... d cost-effectiveness analysis.
@en
Monitored isoniazid prophylaxi ...... d cost-effectiveness analysis.
@nl
type
label
Monitored isoniazid prophylaxi ...... d cost-effectiveness analysis.
@en
Monitored isoniazid prophylaxi ...... d cost-effectiveness analysis.
@nl
prefLabel
Monitored isoniazid prophylaxi ...... d cost-effectiveness analysis.
@en
Monitored isoniazid prophylaxi ...... d cost-effectiveness analysis.
@nl
P2093
P1476
Monitored isoniazid prophylaxi ...... d cost-effectiveness analysis.
@en
P2093
E E Salpeter
G D Sanders
S R Salpeter
P304
P356
10.7326/0003-4819-127-12-199712150-00001
P407
P577
1997-12-01T00:00:00Z